Veru Inc. (NASDAQ:VERU - Get Free Report)'s stock price hit a new 52-week low on Monday . The company traded as low as $3.33 and last traded at $3.49, with a volume of 227729 shares traded. The stock had previously closed at $3.73.
Veru Stock Down 3.7%
The business's 50-day simple moving average is $5.77 and its two-hundred day simple moving average is $5.53. The stock has a market cap of $526.22 million, a P/E ratio of -14.96 and a beta of -0.72.
Veru (NASDAQ:VERU - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.10. Analysts anticipate that Veru Inc. will post -0.22 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. Weaver Consulting Group increased its stake in shares of Veru by 27.4% in the first quarter. Weaver Consulting Group now owns 88,838 shares of the company's stock worth $44,000 after buying an additional 19,133 shares during the period. Allworth Financial LP purchased a new position in shares of Veru in the second quarter worth $45,000. Wells Fargo & Company MN increased its stake in shares of Veru by 37.1% in the fourth quarter. Wells Fargo & Company MN now owns 75,512 shares of the company's stock worth $49,000 after buying an additional 20,430 shares during the period. Integrated Wealth Concepts LLC increased its stake in shares of Veru by 31.3% in the fourth quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company's stock worth $56,000 after buying an additional 20,500 shares during the period. Finally, Cetera Investment Advisers increased its stake in shares of Veru by 26.1% in the fourth quarter. Cetera Investment Advisers now owns 95,210 shares of the company's stock worth $62,000 after buying an additional 19,724 shares during the period. 47.16% of the stock is owned by hedge funds and other institutional investors.
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.